Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists

AIMS: Oral anticoagulation with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) is effective but has significant limitations. AZD0837, a new oral anticoagulant, is a prodrug converted to a selective and reversible direct thrombin inhibitor (AR-H067637). We report from...

Descripción completa

Detalles Bibliográficos
Autores principales: Lip, Gregory Y.H., Rasmussen, Lars H., Olsson, S. Bertil, Jensen, Eva C., Persson, Anders L., Eriksson, Ulf, Wåhlander, Karin F.C.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2009
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2785945/
https://www.ncbi.nlm.nih.gov/pubmed/19690349
http://dx.doi.org/10.1093/eurheartj/ehp318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2785945/
https://www.ncbi.nlm.nih.gov/pubmed/19690349
http://dx.doi.org/10.1093/eurheartj/ehp318

Ejemplares similares